The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of the CDK4 inhibitor PD0332991 in CDK4-amplified liposarcoma.
Mark Andrew Dickson
Consultant or Advisory Role - Pfizer
Mary Louise Keohan
No relevant relationships to disclose
William D. Tap
No relevant relationships to disclose
Cristina Antonescu
No relevant relationships to disclose
Jonathan Landa
No relevant relationships to disclose
Li-Xuan Qin
No relevant relationships to disclose
Eric Gerard Dohrenwend
No relevant relationships to disclose
Dustin Rathbone
No relevant relationships to disclose
Yelena Ustoyev
No relevant relationships to disclose
Mercedes M Condy
No relevant relationships to disclose
Samuel Singer
Consultant or Advisory Role - Pfizer
Gary K. Schwartz
Consultant or Advisory Role - Pfizer